

Patient #	PB Granulocytes JAK2V617F Allele Burden (%)	Experiment*	Patient #	PB Granulocytes JAK2V617F Allele Burden (%)	Experiment
1	80	a, c,d, g	17	70	h
2	60	j	18	89	m
3	35	a, c, d,g	19	0	a,j
4	86	k,l	20	0	a,c
5	45	a,c	21	0	a,c
6	77	a, c,d,g, j, k, l	22	0	a,c
7	35	a	23	0	j.m
8	10	a	24	0	a,c,e
9	75	a, c, d,k,l	25	0	a, b
10	70	k, l	26	0	a, b
11	80	a, e,f	27	0	a, b, c, e,j,m
12	37	a, c, d,e, f,g	28	0	a, b, c, e,j,m
13	65	a,b, c, d,e, f	29	0	a, c
14	65	a, e,f	30	0	h,m
15	70	h	31	0	h.m
16	74	h	32	0	a, b, c,i

***a**: Phenotype of CD34+ cells treated with 5azaD/SAHA; **b**: Apoptosis of CD34+ cells treated with 5azaD/SAHA
c: HPC assay of CD34+ cells treated with 5azaD/SAHA; **d**:JAK2V617F of HPC assayed from CD34+ cells treated with 5azaD/SAHA
e: Migration assay of CD34+ cells treated with 5azaD/SAHA; **f**:JAK2V617F of migrating cells
g: SRC assay of CD34+ cells treated with 5azaD/SAHA; **h**: Phenotype of CD34+ cells treated with JAK Inhibitor 1, AZ1480, Hydroxyurea or Peg-IFN- α 2a
i: chromosomal abnormality of HPC treated with 5azaD/SAHA; **j**: CD34+ cells treated with SAHA alone
k: SRC assay of CD34+ cells treated with 5azaD/TSA; **l**: Phenotype of CD34+ cells treated with 5azaD/TSA
m:CD34+ cells treated with 5azaD alone